The "Aha!" Moment: Breakthrough at the GLP-1 Receptor Few moments in genomic research match the thrill of finding a genetic signal that can plausibly explain differences in medication response
Candidate panels include MRI-PDFF, ELF, PRO-C3, and emerging transcriptomic signatures
They work by increasing incretin levels, which, in turn, increase insulin release and decrease glucagon release
Trulicity belongs to the drug class called glucagon-like peptide-1 (GLP-1) receptor agonists, which includes other medications such as Ozempic, Wegovy, Ryebelsus, Victoza, Saxenda, and Byetta
This partnership of states could present the manufacturers with a willingness to expand the market for these drugs on the condition that the prices come down